These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26297206)

  • 1. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Aerosol Delivery (AAD) technology.
    Denyer J; Nikander K; Smith NJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):165-76. PubMed ID: 16296727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can nanotechnology hit the spot in aerosol-based drug delivery for lung disorders?
    Joshi N
    Ther Deliv; 2018 Mar; 9(4):233-236. PubMed ID: 29495926
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.
    Tolman JA; Williams RO
    Drug Dev Ind Pharm; 2010 Jan; 36(1):1-30. PubMed ID: 19640248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology approaches for inhalation treatment of fibrosis.
    Savla R; Minko T
    J Drug Target; 2013 Dec; 21(10):914-25. PubMed ID: 23978292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of nanotechnology for heart, lung and blood diseases.
    Buxton D
    Expert Opin Drug Deliv; 2006 Mar; 3(2):173-5. PubMed ID: 16506945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled Formulation Design for the Treatment of Lung Infections.
    Garcia-Contreras L; Yadav KS
    Curr Pharm Des; 2015; 21(27):3875-901. PubMed ID: 26290199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
    Iyer R; Hsia CC; Nguyen KT
    Curr Pharm Des; 2015; 21(36):5233-44. PubMed ID: 26412358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.
    Maurya S; Srivastava R; Arfin S; Hawthorne S; Jha NK; Agrawal K; Raj S; Rathi B; Kumar A; Raj R; Agrawal S; Paiva-Santos AC; Malik AA; Dua K; Rana R; Ojha S; Jha SK; Sharma A; Kumar D; El-Zahaby SA; Nagar A
    Nanomedicine (Lond); 2022 Dec; 17(30):2245-2264. PubMed ID: 36975758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhaled medication and inhalation devices for lung disease].
    Solé A; Girón RM
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():19-24. PubMed ID: 26365729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized Medications for Gene and Peptide Therapy.
    Laube BL
    Respir Care; 2015 Jun; 60(6):806-21; discussion 821-4. PubMed ID: 26070576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical nanoparticles for next generation drug delivery to the lungs.
    van Rijt SH; Bein T; Meiners S
    Eur Respir J; 2014 Sep; 44(3):765-74. PubMed ID: 24791828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
    Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
    Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.
    Yadav D; Wairagu PM; Kwak M; Jin JO
    Curr Drug Metab; 2022; 23(11):882-896. PubMed ID: 35927812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal Engineering: Upcoming Paradigm for Efficacious Pulmonary Drug Delivery.
    Desai PP; Mapara SS; Patravale VB
    Curr Pharm Des; 2018; 24(21):2438-2455. PubMed ID: 29773055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.